BioLineRx reports results of additional BL-7040 analyses, shares rise

BioLineRx (BLRX) jumps 7% in premarket trading as the company reports additional results from a Phase 2a study of BL-7040 in IBD.

The company says the new analyses "reinforce the initial positive results of the study" as reported earlier this year.

More specifically, BLRX highlights histological analysis which shows that treated patients saw a significant reduction in neutrophil levels and "also showed a clinical improvement as assessed by their Mayo score." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs